Germany · Delayed Price · Currency is EUR Novavax Company Description
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.
The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 952 |
| CEO | John Jacobs |
Contact Details
Address: 700 Quince Orchard Road Gaithersburg, Delaware 20878 United States | |
| Phone | 240 268 2000 |
| Website | novavax.com |
Stock Details
| Ticker Symbol | NVV1 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US6700024010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Jacobs | Chief Executive Officer |
| James Kelly | Chief Financial Officer |
| Richard Crowley | Chief Operating Officer |